Drugmaker with rare disease work · based in Alameda, United States · founded 1994 · ticker EXEL · exelixis.com
Exelixis works on 5 rare diseases we track, including Familial Medullary Thyroid Carcinoma, Medullary Thyroid Cancer and 3 more. It has 5 active clinical trials, and 3 are looking for volunteers now. It also has 2 FDA-approved rare disease drugs.
Exelixis is an oncology-focused pharmaceutical company best known for cabozantinib, a multikinase inhibitor. It is sold as Cometriq for medullary thyroid cancer and as Cabometyx for kidney cancer, liver cancer and differentiated thyroid cancer, and since March 26, 2025 for previously treated, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older.
Exelixis pipeline
Each row lists the diseases Exelixis is studying at that stage, from the ones closest to approval down to the earliest work.
These are Exelixis trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
3 trials looking for volunteers now
Looking for volunteersPhase 2Recently updatedNCT01639508
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
TestsCabozantinib
For Non-Small Cell Lung Cancer
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment.
RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing
Cabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastaticneuroendocrine tumors.
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastaticrenal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastaticMTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
Its lead pipeline drug, zanzalintinib, is in the Phase 3 STELLAR-311 trial against everolimus in neuroendocrine tumors (NCT06943755). The rest of its pipeline, antibody-drug conjugates and other drugs in early trials, targets common solid tumors.
Where Exelixis trials take place
The trials above run at 193 study sites in 24 countries. Tap a country to see its states, cities and hospitals.
United States
50▼
France
18▼
Italy
18▼
Spain
17▼
Australia
10▼
United Kingdom
10▼
South Korea
8▼
Germany
7▼
Netherlands
7▼
Poland
7▼
Canada
5▼
Belgium
4▼
Rare diseases Exelixis works on
Each disease page lists every open trial, not only Exelixis's, plus approved treatments.
Familial medullary thyroid carcinoma is an autosomal dominant cancer predisposition syndrome caused by germline RET mutations.
How common: Near-complete penetrance by adulthood in RET mutation carriers (varies by specific codon mutation); comprises ~25% of medullary thyroid cancers
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells of the thyroid gland, accounting for 2-4% of all thyroid cancers.
How common: Approximately 1,000-1,200 new cases per year in the U.S.; 2-4% of all thyroid cancers
Neuroendocrine tumors (NETs) grow from hormone-making cells, most often in the small intestine, pancreas, rectum or lungs.
How common: About 244,000 people in the US were living with a neuroendocrineneoplasm, the wider group that includes NETs, in 2021, with about 8.5 new diagnoses per 100,000 people a year (Dasari et al., JAMA Network Open 2025); an earlier estimate for NETs alone was about 171,000 in 2014 (JAMA Oncology 2017)
Pheochromocytoma is a rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla that produces excessive catecholamines (epinephrine and norepinephrine).
How common: About 2 to 8 new cases per million people a year (National Cancer Institute)
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Exelixis's own site is exelixis.com, and our help paying for treatment page lists drugmaker programs and charity funds.
2 shared diseases, including Familial Medullary Thyroid Carcinoma and Medullary Thyroid Cancer
Questions about Exelixis
Exelixis is an oncology-focused pharmaceutical company best known for cabozantinib, a multikinase inhibitor. It is sold as Cometriq for medullary thyroid cancer and as Cabometyx for kidney cancer, liver cancer and differentiated thyroid cancer, and since March 26, 2025 for previously treated, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older. Its lead pipeline drug, zanzalintinib, is in the Phase 3 STELLAR-311 trial against everolimus in neuroendocrine tumors (NCT06943755). The rest of its pipeline, antibody-drug conjugates and other drugs in early trials, targets common solid tumors.
Exelixis has active programs across 5 rare diseases: Familial Medullary Thyroid Carcinoma, Medullary Thyroid Cancer, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Exelixis is a diversified pharmaceutical company headquartered in Alameda, United States, founded in 1994. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 5 active rare disease programs including Familial Medullary Thyroid Carcinoma, Medullary Thyroid Cancer, Neuroendocrine Tumors. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Exelixis, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
Exelixis has 2 FDA-approved drugs with a rare disease use that we track, as of November 2026.
Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.
Yes, for 2 of its FDA-approved rare disease medicines that we track, each checked on Exelixis' own website.
Cometriq: Exelixis Access Services (EASE), 1-844-900-3273. Offers copay help with private insurance, a free medicine program and insurance help. Checked November 15, 2026.
Cabometyx: Exelixis Access Services (EASE), 1-844-900-3273. Offers copay help with private insurance, a free medicine program and insurance help. Checked November 17, 2026.
Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.
Eligibility is decided by each program, so call the number listed before a prescription is filled.
Exelixis was founded in 1994 and is headquartered in Alameda, United States. The company has been active for 32 years. It trades publicly under the ticker symbol EXEL.